Linking fecal microbiota composition to anti-saccharomyces cerevisiae antibody (ASCA) production in inflammatory bowel disease (IBD)patients.

Linking fecal microbiota composition to anti-saccharomyces cerevisiae antibody (ASCA) production in inflammatory bowel disease (IBD)patients. - Microbiota in inflammatory bowel disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44343

Enrollment

Registered

2018-01-10

Start date

2018-11-13

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intestinal inflammation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: For all groups: - Age from 18 years, either male or female - Ability to give informed consent - No use of antibiotics or antifungals 3 months prior to sample collection. ;Group specific inclusion criteria: - Group 1 and 2 the patients have been diagnosed with CD. - Group 3 patients have been diagnosed with UC patients. - Group 4 People have not been diagnosed with IBD.

Exclusion criteria

Exclusion criteria: Inability to give informed consent

Design outcomes

Primary

Measure	Time frame
1) A correlation in CD patiënts between C.albicans strains and ASCA titer in blood. 2) A correlation in CD patiënts between fecal microbial composition and ASCA titer in blood.	—

Secondary

Measure	Time frame
The secondary study parameters are based on a correlation between disease severity (measured by determination of fecal calprotectin) and fecal microbial composition/ fecal C.albicans strains in CD, UC and healthy volunteers.	—

Countries

Netherlands

Outcome results